We are live on ! Find out more
ARTA

A.R.T. Advisors Portfolio holdings

AUM $1.79M
1-Year Est. Return 57.47%
This Fund
S&P 500
This Quarter Est. Return
+7.26%
1 Year Est. Return
+57.47%
3 Year Est. Return
+81.79%
5 Year Est. Return
+178.88%
10 Year Est. Return
–
AUM
$2.46B
AUM Growth
-$34.2M
Cap. Flow
-$114M
Cap. Flow %
-4.63%
Top 10 Hldgs %
7.2%
Holding
2,015
New
556
Increased
372
Reduced
436
Closed
645

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$17.3M
2
DIS icon
Walt Disney
DIS
+$17.3M
3
CMG icon
Chipotle Mexican Grill
CMG
+$16M
4
NKTR icon
Nektar Therapeutics
NKTR
+$15M
5
HAL icon
Halliburton
HAL
+$13.9M

Top Sells

Rank Stock Value
1
ULTA icon
Ulta Beauty
ULTA
+$24.9M
2
BA icon
Boeing
BA
+$23.2M
3
EA icon
Electronic Arts
EA
+$20M
4
FIVE icon
Five Below
FIVE
+$19.6M
5
CAR icon
Avis
CAR
+$13.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 18.32%
2 Industrials 13.59%
3 Technology 11.91%
4 Healthcare 11.79%
5 Financials 9.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VBIV
1351
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$32K ﹤0.01%
390
+8
+2% +$773
ATYR
1352
aTyr Pharma
ATYR
$48.4M
$30K ﹤0.01%
+2,364
New +$56.1K
TOPS icon
1353
TOP Ships
TOPS
$4.11M
– –
0
– –
ALTO icon
1354
Alto Ingredients
ALTO
$345M
$27K ﹤0.01%
10,591
-9,308
-47% -$29.6K
LPCN icon
1355
Lipocine
LPCN
$17.6M
$25K ﹤0.01%
+1,139
New +$27.2K
RGLS
1356
DELISTED
Regulus Therapeutics
RGLS
$24K ﹤0.01%
304
-1,108
-78% -$91.7K
HIND
1357
Vyome Holdings
HIND
$14M
– –
0
– –
OMED
1358
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$24K ﹤0.01%
+10,429
New +$30.4K
LCTX icon
1359
Lineage Cell Therapeutics
LCTX
$267M
$23K ﹤0.01%
13,294
-87,331
-87% -$176K
RVP icon
1360
Retractable Technologies
RVP
$20.1M
$23K ﹤0.01%
31,308
-52,141
-62% -$44.4K
SNMX
1361
DELISTED
Senomyx, Inc.
SNMX
$23K ﹤0.01%
19,351
+7,071
+58% +$8.46K
FRTX
1362
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$22K ﹤0.01%
62
-43
-41% -$20.2K
ALO
1363
DELISTED
Alio Gold Inc
ALO
$22K ﹤0.01%
+15,439
New +$27.4K
ARDM
1364
DELISTED
Aradigm Corp Common Stock
ARDM
$17K ﹤0.01%
11,994
-40,653
-77% -$60K
BLRX
1365
BioLineRX
BLRX
$12.2M
$15K ﹤0.01%
28
-30
-52% -$15.9K
ENSV
1366
DELISTED
Enservco Corp.
ENSV
$15K ﹤0.01%
+904
New +$15.2K
CYTO
1367
DELISTED
Altamira Therapeutics Ltd
CYTO
$15K ﹤0.01%
+2
New +$21.1K
GNMX
1368
DELISTED
Aevi Genomic Medicine Inc
GNMX
$15K ﹤0.01%
+13,594
New +$20.7K
ARMP icon
1369
Armata Pharmaceuticals
ARMP
$174M
$11K ﹤0.01%
+724
New +$11.8K
AAT
1370
American Assets Trust
AAT
$1.48B
– –
-22,300
Closed -$745K
ABG icon
1371
Asbury Automotive
ABG
$4.49B
– –
-4,000
Closed -$270K
ABT icon
1372
Abbott
ABT
$187B
– –
-9,496
Closed -$569K
ABUS icon
1373
Arbutus Biopharma
ABUS
$871M
– –
-14,491
Closed -$72K
ACCO icon
1374
Acco Brands
ACCO
$401M
– –
-14,995
Closed -$188K
ACGL icon
1375
Arch Capital
ACGL
$37.2B
– –
-58,800
Closed -$1.68M
53 54
55
56 57

Similar funds

MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
FFIM
Founders Fund III Management San Francisco, California $435K AUM
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
CCM
Copernicus Capital Management San Francisco, California $8.26M AUM 37.91% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM

A.R.T. Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, A.R.T. Advisors held 2,015 positions worth $2.46B, down 1.4% from $2.49B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.

A.R.T. Advisors withdrew a net $114M in Q2 2018, closing 645 positions and reducing 436 holdings. Its most notable exit was Five Below, an estimated $19.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Technology.

Against the trend, A.R.T. Advisors opened a new position in Celgene Corp worth $16.6M.

  • A.R.T. Advisors's largest Q2 2018 buy was Celgene Corp: 208,600 shares worth $16.6M.
  • A.R.T. Advisors added most to Walt Disney in Q2 2018, an estimated $17.3M increase.
  • A.R.T. Advisors's biggest Q2 2018 reduction was Ulta Beauty, cutting an estimated $24.9M.
  • A.R.T. Advisors fully exited Five Below in Q2 2018, selling an estimated $19.6M.
  • A.R.T. Advisors's ten largest holdings make up 7.2% of its $2.46B portfolio in Q2 2018.
  • A.R.T. Advisors opened 556 new positions and closed 645 in Q2 2018.
  • A.R.T. Advisors's portfolio value fell 1.4% quarter-over-quarter to $2.46B.

Based on A.R.T. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.